2018
DOI: 10.1210/jc.2018-00163
|View full text |Cite
|
Sign up to set email alerts
|

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

Abstract: PurposeIn women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO).MethodsWomen who completed ABL or PBO treatment in ACTIVE were eligible to receive up to 24 months of ALN. We evaluated the incidence of vertebral and nonvertebral fractures and changes in bone mineral density (BMD) during the entire 43-month period from ACTIVE baseline to the end of ACTIVExtend and for the 24-m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

6
133
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 148 publications
(147 citation statements)
references
References 15 publications
6
133
0
Order By: Relevance
“…This new peptide has 41% homology to PTH (1‐34) and 76% homology to PTHrP (1‐34). This peptide was selected to retain stability and potent bone anabolic activity and a low calcium‐mobilization potential . Phase III clinical trials reported that abaloparatide (at 80 μg/d) was similar, if not superior, to teriparatide (at 20 μg/d) in increasing bone mineral density in osteoporotic postmenopausal women with lower serum CTX levels, the marker for bone resorption, than in patients treated with teriparatide …”
Section: Introductionmentioning
confidence: 99%
“…This new peptide has 41% homology to PTH (1‐34) and 76% homology to PTHrP (1‐34). This peptide was selected to retain stability and potent bone anabolic activity and a low calcium‐mobilization potential . Phase III clinical trials reported that abaloparatide (at 80 μg/d) was similar, if not superior, to teriparatide (at 20 μg/d) in increasing bone mineral density in osteoporotic postmenopausal women with lower serum CTX levels, the marker for bone resorption, than in patients treated with teriparatide …”
Section: Introductionmentioning
confidence: 99%
“…It is interesting to note that the BMD increments found with 18 months of Dmab treatment after 18 months of TPTD were quite large, especially in the spine and total hip. These BMD gains appear larger than those found in other studies when alendronate is administered after teriparatide or abaloparatide . Several other studies suggest that Dmab treatment enhances BMD gain after TPTD to a greater degree than bisphosphonates .…”
Section: Discussionmentioning
confidence: 52%
“…Previous trials have shown that antiresorptive treatment after anabolic therapy preserves the benefits conferred by anabolic therapy and that in the absence of such antiresorptive treatment, the BMD gains are gradually lost . The results of ACTIVExtend demonstrate that the skeletal benefits achieved after 18 months of abaloparatide therapy are extended by subsequent treatment with alendronate, providing further evidence that anabolic therapy followed by an antiresorptive appears to be a compelling strategy to prevent fractures in postmenopausal women with osteoporosis who are at high risk for fracture …”
Section: Discussionmentioning
confidence: 94%
“…In ACTIVE, patients were randomized 1:1:1 to placebo or abaloparatide 80 μg daily in a blinded fashion or to open‐label teriparatide 20 μg daily for 18 months . The design and methodology of ACTIVExtend (NCT01657162) have been described in detail . ACTIVExtend was conducted in accordance with the Declaration of Helsinki and in compliance with Good Clinical Practice guidelines and all other applicable local regulatory and ethical requirements.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation